(CercleFinance.com) – UCB is down nearly 1% in Brussels, against the backdrop of comments from Oddo BHF which maintains its ‘outperformance’ opinion, but expects ‘another complicated five months before the expected approval of Bimzelx’, and adjusts its target price from 100 to 98 euros.
‘2022 and 2023 will be the company’s low point years before a return to strong growth driven by Bimzelx, Roza and Zilucoplan in particular’, judges the analyst, who models a 2022/26 EPS TMVA of +23% for the Belgian pharmaceutical group.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
